The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials

touchEXPERT OPINIONS for touchHAEMATOLOGY Three internationally renowned multiple myeloma experts share insights into the unmet treatment needs for patients with relapsed/refractory multiple myeloma, the rationale for emerging protein degradation and immunomodulation-based therapies, and the latest data and ongoing clinical trials for these investigational agents.   The experts Prof. Cristina Gasparetto - Duke Cancer Institute, Durham, NC, USA Prof. Sagar Lonial - Emory University, Atlanta, GA, USA Prof. Sundar Jagannath - Tisch Cancer Institute, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchhaematologyime.org/eo-in-rrmm